---
schema_version: "secwatch.filing_event.v1"
accession: "0001501697-25-000021"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:21:09.239356+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart

## Summary
- Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.
- Cash charges of ~$3.3M for severance and termination-related costs; substantially complete in Q3 2025.
- COO Mary DiBiase, CCO Mark Baldry, CLO Natasha Thoren terminated; CMO Christophe Arbet-Engels resigns.
- John Volpone appointed COO in addition to his role as President; Executive Chairman Adam Craig oversees clinical development.
- Restructuring aims to focus resources on completing the 4WARD Phase 3 trial for chronic neutropenia.

## SEC filing metadata
- accession: 0001501697-25-000021
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/0001501697-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/xfor-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001501697-25-000021
- JSON: https://secwatch.observer/filing/0001501697-25-000021.json
- Plain text: https://secwatch.observer/filing/0001501697-25-000021.txt

## Key facts
- Restructurings & Charges
  X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.3 million for severance and other employee termination-related costs affecting the Company (reduce its workforce by approximately 50%).
  - Type: restructuring
  - Charge: approximately $3.3 million for severance and other employee termination-related costs
  - Affected area: the Company
  - Headcount: reduce its workforce by approximately 50%
  source text: On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‐term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/0001501697-25-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.